Loading...
XSHG
603858
Market cap2.53bUSD
Dec 05, Last price  
16.96CNY
1D
0.30%
1Q
-11.30%
Jan 2017
-76.86%
IPO
-75.09%
Name

Shandong Buchang Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XSHG:603858 chart
P/E
P/S
1.63
EPS
Div Yield, %
0.74%
Shrs. gr., 5y
-0.58%
Rev. gr., 5y
-5.04%
Revenues
11.01b
-16.91%
5,871,833,2507,036,593,8278,591,698,81310,333,616,10211,655,627,38712,320,883,10113,863,918,66113,664,752,61314,255,454,95916,006,714,33915,762,679,80214,951,252,69413,245,133,30211,005,794,900
Net income
0k
-100.00%
1,228,166,4911,251,331,2991,168,574,7541,323,627,3003,536,764,3641,769,364,6461,637,952,3171,888,405,3721,945,997,1731,860,894,3351,162,117,9190318,973,3240
CFO
940m
P
01,349,185,8551,113,956,7901,780,581,7632,120,730,7161,668,783,0821,961,975,6032,050,837,3142,621,333,5281,958,763,3871,320,513,3692,755,627,692-164,259,736939,950,568
Dividend
Aug 20, 20240.126 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Shandong Buchang Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of medicines in China. It offers medicines to treat cardiac and cerebral vascular, urinary and digestive, respiratory, gynecological, and other diseases, as well as diabetes. The company was founded in 1993 and is based in Heze, China. Shandong Buchang Pharmaceuticals Co., Ltd. was a former subsidiary of Shanghai Zhangjiang (Group) Co., Ltd.
IPO date
Nov 18, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT